miRNA Details
miRNA General Information | |||||
---|---|---|---|---|---|
miRNA Mature ID | hsa-miR-181b-5p | ||||
miRNA Stemloop AC | MI0000270 | MI0000683 | ||||
miRNA Stemloop ID | hsa-mir-181b-1 | hsa-mir-181b-2 | ||||
Sequence | aacauucauugcugucggugggu | ||||
TTD Target(s) Regulated by This miRNA | Estrogen receptor (ESR) | Successful Target | Target Info | [1] | |
Glutamate receptor AMPA 2 (GRIA2) | Successful Target | Target Info | [2] | ||
T-cell leukemia/lymphoma protein 1A (TCL1A) | Literature-reported Target | Target Info | [3] | ||
Protein(s) Regulated by This miRNA | Adenylate cyclase type 9 | Regulated Protein | [4] | ||
Bcl-2-like protein 11 | Regulated Protein | [5] | |||
Caspase recruitment domain-containing protein 10 | Regulated Protein | [6] | |||
E3 ubiquitin-protein ligase RING2 | Regulated Protein | [7] | |||
Elastin | Regulated Protein | [8] | |||
Hexokinase-2 | Regulated Protein | [9] | |||
Homeobox protein CDX-2 | Regulated Protein | [10] | |||
Homeobox protein SIX2 | Regulated Protein | [11] | |||
Importin subunit alpha-3 | Regulated Protein | [12] | |||
Metalloproteinase inhibitor 3 | Regulated Protein | [13] | |||
Nuclear factor 1 A-type | Regulated Protein | [14] | |||
Pre-B-cell leukemia transcription factor 3 | Regulated Protein | [15] | |||
Programmed cell death protein 10 | Regulated Protein | [16] | |||
Programmed cell death protein 4 | Regulated Protein | [17] | |||
Ras association domain-containing protein 1 | Regulated Protein | [18] | |||
Ras-related protein Rap-1b | Regulated Protein | [19] | |||
Serine/threonine-protein kinase NLK | Regulated Protein | [10] | |||
Transcription factor GATA-6 | Regulated Protein | [10] | |||
Transcription factor GATA-6 | Regulated Protein | [16] | |||
Transmembrane emp24 domain-containing protein 7 | Regulated Protein | [20] | |||
Ubiquitin carboxyl-terminal hydrolase CYLD | Regulated Protein | [21] | |||
Ubiquitin carboxyl-terminal hydrolase CYLD | Regulated Protein | [22] | |||
Visinin-like protein 1 | Regulated Protein | [2] | |||
Zinc finger protein PLAG1 | Regulated Protein | [24] | |||
References | |||||
REF 1 | The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol. 2007 May;21(5):1132-47. | ||||
REF 2 | Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet. 2008 Apr 15;17(8):1156-68. | ||||
REF 3 | Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006 Dec 15;66(24):11590-3. | ||||
REF 4 | miR-181b promotes cell proliferation and reduces apoptosis by repressing the expression of adenylyl cyclase 9 (AC9) in cervical cancer cells.FEBS Lett. 2014 Jan 3;588(1):124-30. | ||||
REF 5 | MiR-181b promotes chemoresistance in breast cancer by regulating Bim expression.Oncol Rep. 2016 Feb;35(2):683-90. | ||||
REF 6 | MicroRNA-181b inhibits thrombin-mediated endothelial activation and arterial thrombosis by targeting caspase recruitment domain family member 10.FASEB J. 2016 Sep;30(9):3216-26. | ||||
REF 7 | Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell. 2011 Aug 16;20(2):187-99. | ||||
REF 8 | MicroRNA-181b Controls Atherosclerosis and Aneurysms Through Regulation of TIMP-3 and Elastin.Circ Res. 2017 Jan 6;120(1):49-65. | ||||
REF 9 | Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.Oncol Rep. 2017 Mar;37(3):1430-1436. | ||||
REF 10 | Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells.Hepatology. 2009 Aug;50(2):472-80. | ||||
REF 11 | MiR-181b targets Six2 and inhibits the proliferation of metanephric mesenchymal cells in vitro.Biochem Biophys Res Commun. 2013 Nov 1;440(4):495-501. | ||||
REF 12 | Upregulation of miR-181s reverses mesenchymal transition by targeting KPNA4 in glioblastoma.Sci Rep. 2015 Aug 18;5:13072. | ||||
REF 13 | TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3.Oncogene. 2010 Mar 25;29(12):1787-97. | ||||
REF 14 | MicroRNA 21 (miR-21) and miR-181b couple with NFI-A to generate myeloid-derived suppressor cells and promote immunosuppression in late sepsis.Infect Immun. 2014 Sep;82(9):3816-25. | ||||
REF 15 | Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.Blood. 2012 Mar 8;119(10):2314-24. | ||||
REF 16 | MicroRNA Stability in Postmortem FFPE Tissues: Quantitative Analysis Using Autoptic Samples from Acute Myocardial Infarction Patients.PLoS One. 2015 Jun 5;10(6):e0129338. | ||||
REF 17 | miR-181b functions as an oncomiR in colorectal cancer by targeting PDCD4. Protein Cell. 2016 Oct;7(10):722-734. | ||||
REF 18 | PML/RAR-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.Cancer Res. 2015 Aug 15;75(16):3411-24. | ||||
REF 19 | miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells.Med Oncol. 2014 Apr;31(4):892. | ||||
REF 20 | miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients.Biochem Biophys Res Commun. 2012 Apr 27;421(1):4-8. | ||||
REF 21 | STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 2010 Aug 27;39(4):493-506. | ||||
REF 22 | Reciprocal activation between STAT3 and miR-181b regulates the proliferation of esophageal cancer stem-like cells via the CYLD pathway.Mol Cancer. 2016 May 17;15(1):40. | ||||
REF 23 | Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet. 2008 Apr 15;17(8):1156-68. | ||||
REF 24 | miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia.Blood. 2009 Oct 8;114(15):3255-64. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.